Dual‐Sensing Nanoreporter for Dynamic and High‐Throughput Monitoring of Immune Checkpoint Inhibitor Responses in Tumor‐Derived Organoids
Source abstract
Abstract
Abstract Heterogenous immune responses to checkpoint blockade therapy remain a major challenge to early prediction of treatment efficacy. Current methods of evaluating treatment efficacy in tumors are ineffective in accurately monitoring the disease status after immunotherapy early on. This study reports an immune response monitoring strategy that longitudinally reports on two crucial protease activities involved in T cell‐mediated target cell death, granzyme B (GrzB) and downstream caspase 3 (Casp3), during and after immune checkpoint antibody treatment. Specifically, activatable nanoreporters are engineered to sensitively and selectively capture the activity of GrzB and Casp3 enzymes in tumor cells triggered by cytotoxic T cells in real‐time, providing a direct readout of the tumor response to immune checkpoint inhibitors (ICIs). Furthermore, incorporating 3D tumor‐derived organoids and ex vivo cultures on microfluidic devices with nanoreporters enables high‐throughput screening of various ICIs and their combinations in immunocompetent tumor models. These findings suggest that efficient monitoring of dynamic immunological processes in the tumor microenvironment could help uncover mechanisms associated with ICI response or resistance. It is further anticipated that combining the dual‐sensing nanoreporter with tumor‐derived organoid‐on‐chip technology could lead to an early prediction of treatment outcomes with high fidelity and accelerate the development of optimal treatment in immuno‐oncology.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering University of Massachusetts Amherst MA 01003 USA
Department of Biomedical Engineering University of Massachusetts Amherst MA 01003 USA
Department of Veterinary and Animal Sciences University of Massachusetts Amherst MA 01003 USA
Center for Bioactive Delivery Institute for Applied Life Sciences University of Massachusetts Amherst MA 01003 USA
Funding
American Cancer Society · National Institutes of Health
References (59)
Show source-provided references
1. 10.1186/s13045-019-0779-510.1186/s13045-019-0779-5 ↗
2. 10.1038/nbt113710.1038/nbt1137 ↗
3. 10.3390/antib903003410.3390/antib9030034 ↗
4. 10.1097/PPO.000000000000030310.1097/PPO.0000000000000303 ↗
5. 10.1172/JCI8001110.1172/JCI80011 ↗
6. 10.1186/s13045-018-0578-410.1186/s13045-018-0578-4 ↗
7. 10.3389/fonc.2021.61733510.3389/fonc.2021.617335 ↗
8. 10.1093/annonc/mdz00310.1093/annonc/mdz003 ↗
9. 10.1200/JCO.2015.61.687010.1200/JCO.2015.61.6870 ↗
10. 10.1158/2159-8290.CD-17-083310.1158/2159-8290.CD-17-0833 ↗
11. 10.1371/journal.pone.019349810.1371/journal.pone.0193498 ↗
12. 10.1158/1078-0432.CCR-15-068510.1158/1078-0432.CCR-15-0685 ↗
13. 10.3390/cancers1306129210.3390/cancers13061292 ↗
14. 10.1126/science.278.5345.196610.1126/science.278.5345.1966 ↗
15. 10.1074/jbc.274.30.2115510.1074/jbc.274.30.21155 ↗
16. 10.1083/jcb.20021015810.1083/jcb.200210158 ↗
17. 10.1084/jem.192.10.140310.1084/jem.192.10.1403 ↗
18. 10.1146/annurev.immunol.20.100201.13173010.1146/annurev.immunol.20.100201.131730 ↗
19. 10.3389/fimmu.2022.86709810.3389/fimmu.2022.867098 ↗
20. 10.1084/jem.186.8.132310.1084/jem.186.8.1323 ↗
21. 10.1038/sj.cdd.440224410.1038/sj.cdd.4402244 ↗
22. 10.1038/373444a010.1038/373444a0 ↗
23. 10.1007/s00262010019110.1007/s002620100191 ↗
24. 10.1046/j.1365-2567.1998.00448.x10.1046/j.1365-2567.1998.00448.x ↗
25. Dawn of Monitoring Regulatory T Cells in (Pre‐)clinical Studies: Their Relevance Is Slowly Recognised. – Abstract – Europe PMC https://www.europepmc.org/article/pmc/pmc7142310(accessed: April 2020).
26. 10.1073/pnas.160345511310.1073/pnas.1603455113 ↗
27. 10.1074/jbc.273.42.2736410.1074/jbc.273.42.27364 ↗
28. 10.1016/j.chembiol.2005.03.00610.1016/j.chembiol.2005.03.006 ↗
29. 10.1096/fj.07-09923410.1096/fj.07-099234 ↗
30. 10.1038/nprot.2009.22310.1038/nprot.2009.223 ↗
31. 10.1038/ncomms315710.1038/ncomms3157 ↗
32. 10.1073/pnas.180533311610.1073/pnas.1805333116 ↗
33. 10.3390/ijms1604671810.3390/ijms16046718 ↗
34. 10.1126/sciadv.abc277710.1126/sciadv.abc2777 ↗
35. 10.1073/pnas.120312910910.1073/pnas.1203129109 ↗
36. 10.1039/C3MH00106G10.1039/C3MH00106G ↗
37. 10.1038/s41565-018-0344-310.1038/s41565-018-0344-3 ↗
38. 10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
39. 10.1007/s00289-019-02924-710.1007/s00289-019-02924-7 ↗
40. 10.1039/C8LC00322J10.1039/C8LC00322J ↗
41. 10.1038/ncomms1457210.1038/ncomms14572 ↗
42. 10.1080/2162402X.2017.129429910.1080/2162402X.2017.1294299 ↗
43. 10.1186/s13578-018-0232-410.1186/s13578-018-0232-4 ↗
44. 10.1158/2326-6066.CIR-14-011810.1158/2326-6066.CIR-14-0118 ↗
45. 10.1084/jem.2016080110.1084/jem.20160801 ↗
46. 10.1200/EDBK_24083710.1200/EDBK_240837 ↗
47. 10.3389/fcell.2020.0067210.3389/fcell.2020.00672 ↗
48. 10.1186/s13045-019-0804-810.1186/s13045-019-0804-8 ↗
49. 10.1172/JCI9611310.1172/JCI96113 ↗
50. 10.1158/0008-5472.CAN-20-318210.1158/0008-5472.CAN-20-3182 ↗
51. 10.1038/s41598-022-07153-z10.1038/s41598-022-07153-z ↗
52. 10.1038/nature1067310.1038/nature10673 ↗
53. 10.1038/s12276-018-0191-110.1038/s12276-018-0191-1 ↗
54. 10.1056/NEJMoa150764310.1056/NEJMoa1507643 ↗
55. 10.1056/NEJMra170348110.1056/NEJMra1703481 ↗
56. 10.1093/annonc/mdv38310.1093/annonc/mdv383 ↗
57. 10.1016/j.clon.2016.11.00710.1016/j.clon.2016.11.007 ↗
58. 10.1158/1078-0432.CCR-09-162410.1158/1078-0432.CCR-09-1624 ↗
59. 10.1158/1078-0432.CCR-13-089510.1158/1078-0432.CCR-13-0895 ↗